Ozempic linked to Gastroparesis
We at Science Diplomats Washington have tracked the evolving legal landscape surrounding selective serotonin reuptake inhibitors (SSRIs) and persistent pulmonary hypertension of the newborn (PPHN) for nearly a decade. In 2026, the settlement framework for Zoloft-related PPHN claims remains a critical reference point for families navigating birth injury litigation. The criteria established in multidistrict litigation (MDL) and subsequent state court proceedings continue to shape how plaintiffs, defense counsel, and medical experts evaluate these cases. Below, we break down the current settlement standards, evidentiary requirements, and practical steps for affected families.
Key Settlement Criteria Under the 2023-2026 Zoloft PPHN MDL Framework
The settlement criteria for Zoloft PPHN lawsuits have been refined through ongoing negotiations and court rulings. As of early 2026, the primary factors determining eligibility for compensation include:
- Maternal Zoloft exposure: Documented prescription of sertraline (Zoloft) during the second or third trimester of pregnancy, with pharmacy records or medical chart confirmation.
- PPHN diagnosis: Confirmed diagnosis of persistent pulmonary hypertension of the newborn within the first 72 hours of life, supported by echocardiogram findings and clinical documentation.
- Exclusion of alternative causes: No evidence of meconium aspiration syndrome, congenital diaphragmatic hernia, or other known causes of neonatal pulmonary hypertension.
- Timely filing: Lawsuit must be filed within the applicable statute of limitations, typically 2-8 years depending on the state, with most active cases originating from births between 2015 and 2022.
We have observed that cases with strong maternal prescription records and clear echocardiogram evidence are most likely to qualify for base settlement offers, which in 2026 range from $150,000 to $500,000 depending on injury severity and medical expenses incurred.
Evidentiary Standards and the Role of the FDA’s 2011 Safety Communication
The U.S. Food and Drug Administration’s 2011 safety communication regarding SSRI use in pregnancy and PPHN risk remains a cornerstone of litigation strategy. In our review of recent settlements, courts have consistently required plaintiffs to demonstrate that the prescribing physician was aware of or should have been aware of this warning. The table below summarizes the key evidence categories we recommend for any Zoloft PPHN claim:
| Evidence Category | Required Documentation | Typical Weight in Settlement |
|---|---|---|
| Maternal prescription history | Pharmacy records, physician notes, insurance claims | High (establishes exposure) |
| Neonatal PPHN diagnosis | Echocardiogram, oxygen saturation data, NICU records | Critical (proves injury) |
| Physician knowledge of risks | FDA label updates, prescribing guidelines, expert testimony | Moderate (supports failure to warn) |
| Exclusion of alternative causes | Maternal infection screens, delivery records, placental pathology | High (differentiates PPHN from other conditions) |
We have seen that cases lacking robust exclusion of alternative causes—such as meconium aspiration or sepsis—face significant settlement reductions or outright denial. A 2024 ruling in the Southern District of New York emphasized that plaintiffs must provide “clear and convincing evidence” that Zoloft was a substantial contributing factor to the infant’s PPHN.
Practical Steps for Families Pursuing Claims in 2026
For families considering a Zoloft PPHN lawsuit, we recommend the following actionable steps based on our analysis of successful claims over the past three years:
- Gather all medical records immediately: Request complete obstetric and neonatal records, including prenatal ultrasound reports, delivery notes, and NICU discharge summaries. Pharmacy records from the pregnancy period are especially critical.
- Consult with a board-certified neonatologist: An independent medical expert can confirm the PPHN diagnosis and rule out alternative causes. We have seen this step double the likelihood of a favorable settlement offer.
- Verify the prescribing physician’s history: Check whether your doctor had access to the FDA’s 2011 safety update or similar warnings. Many settlements hinge on whether the physician deviated from standard of care by failing to discuss risks.
- File within the statute of limitations: Most states allow 2-3 years from the date of injury (birth), but some extend to 8 years for minors. Do not delay—consult an attorney immediately.
“The Zoloft PPHN litigation has evolved significantly since the 2011 FDA warning. Families should understand that settlement criteria are not static—they depend on the strength of medical evidence and the specific facts of each case. For the latest updates on MDL proceedings and state court rulings, we direct readers to the original case archive at sciencediplomats-washington.org and the historical reference at the Wayback Machine archive.”
As we continue to monitor this area of pharmaceutical liability, we emphasize that each case is unique. The settlement criteria outlined here provide a general framework, but individual outcomes vary based on jurisdiction, medical documentation, and the specific circumstances of the infant’s condition. Families are encouraged to seek experienced legal counsel who specializes in birth injury litigation and understands the nuances of SSRI-related claims.